This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and toxicology/pharmacology testing for new cancer prevention and treatment therapies. IITRI, a division of the Illinois Institute of Technology, has extensive experience providing these preclinical drug development services to federal agencies through various IDIQ contracts. The contract has no set-aside designation.
Under this IDIQ, IITRI has been awarded several delivery orders to date. These include a $532,562 firm fixed price task order to evaluate a breast cancer prevention agent, a $3,033,668 firm fixed price task order for preclinical development of an RNA vaccine for prostate cancer immunoprevention, and a $2,398 cost-plus-fixed-fee task order for a contract orientation and kickoff meeting. The contracted work is primarily performed at IITRI's facilities in Chicago, Illinois. These task orders demonstrate the breadth of preclinical research activities supported by the overall PREVENT program, which aims to accelerate the development of promising cancer prevention and treatment agents.
Generated 12/18/24, 9:06 AM